TY - JOUR
T1 - Concurrent chemotherapy improves the overall survival of patients irradiated for locally recurrent bladder cancer
AU - Rades, Dirk
AU - Manig, Lisa
AU - Janssen, Stefan
AU - Schild, Steven E.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/3
Y1 - 2017/3
N2 - Aim: To investigate the predictive value of several factors, including concurrent chemotherapy, for overall survival of patients irradiated for locally recurrent bladder cancer. Patients and Methods: Thirty patients irradiated for local recurrence of bladder cancer were included; 14 received concurrent chemotherapy. Ten factors were analyzed for overall survival: gender, age, period from bladder cancer diagnosis to irradiation of local recurrence, Karnofsky performance scale, tumour grading, pack-years smoked, smoking during radiotherapy, radiation dose, interruption of radiotherapy and concurrent chemotherapy. Results: On univariate analyses, significantly longer overall survival was found for those with age 76 years (p=0.024), better performance status (p<0.001) and those treated with concurrent chemotherapy (p<0.001). On Cox regression analysis, concurrent chemotherapy remained significantly associated with survival (risk ratio 3.82, p=0.013); a trend for association was found for performance status (risk ratio 2.50, p=0.076). Conclusion: Addition of concurrent chemotherapy to radiotherapy for locally recurrent bladder cancer resulted in improved overall survival. Concurrent radiochemotherapy should be considered when this is clinically reasonable for such patients.
AB - Aim: To investigate the predictive value of several factors, including concurrent chemotherapy, for overall survival of patients irradiated for locally recurrent bladder cancer. Patients and Methods: Thirty patients irradiated for local recurrence of bladder cancer were included; 14 received concurrent chemotherapy. Ten factors were analyzed for overall survival: gender, age, period from bladder cancer diagnosis to irradiation of local recurrence, Karnofsky performance scale, tumour grading, pack-years smoked, smoking during radiotherapy, radiation dose, interruption of radiotherapy and concurrent chemotherapy. Results: On univariate analyses, significantly longer overall survival was found for those with age 76 years (p=0.024), better performance status (p<0.001) and those treated with concurrent chemotherapy (p<0.001). On Cox regression analysis, concurrent chemotherapy remained significantly associated with survival (risk ratio 3.82, p=0.013); a trend for association was found for performance status (risk ratio 2.50, p=0.076). Conclusion: Addition of concurrent chemotherapy to radiotherapy for locally recurrent bladder cancer resulted in improved overall survival. Concurrent radiochemotherapy should be considered when this is clinically reasonable for such patients.
UR - http://www.scopus.com/inward/record.url?scp=85015926135&partnerID=8YFLogxK
U2 - 10.21873/anticanres.11474
DO - 10.21873/anticanres.11474
M3 - Journal articles
C2 - 28314322
AN - SCOPUS:85015926135
SN - 0250-7005
VL - 37
SP - 1485
EP - 1488
JO - Anticancer Research
JF - Anticancer Research
IS - 3
ER -